{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T11:37:10Z","timestamp":1772537830383,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The Fanconi Anemia (FA) pathway is essential for human cells to maintain genomic integrity following DNA damage. This pathway is involved in repairing damaged DNA through homologous recombination. Cancers with a defective FA pathway are expected to be more sensitive to cross-link based therapy or PARP inhibitors. To evaluate downstream effectors of the FA pathway, we studied the expression of 734 different micro RNAs (miRNA) using NanoString nCounter miRNA array in two FA defective lung cancer cells and matched control cells, along with two lung tumors and matched non-tumor tissue samples that were deficient in the FA pathway. Selected miRNA expression was validated with real-time PCR analysis. Among 734 different miRNAs, a cluster of microRNAs were found to be up-regulated including an important cancer related micro RNA, miR-200C. MiRNA-200C has been reported as a negative regulator of epithelial-mesenchymal transition (EMT) and inhibits cell migration and invasion by promoting the upregulation of E-cadherin through targeting ZEB1 and ZEB2 transcription factors. miRNA-200C was increased in the FA defective lung cancers as compared to controls. AmpliSeq analysis showed significant reduction in ZEB1 and ZEB2 mRNA expression. Our findings indicate the miRNA-200C potentially play a very important role in FA pathway downstream regulation.<\/jats:p>","DOI":"10.1038\/s41598-021-83884-9","type":"journal-article","created":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T11:03:35Z","timestamp":1614164615000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["MiRNA-200C expression in Fanconi anemia pathway functionally deficient lung cancers"],"prefix":"10.1038","volume":"11","author":[{"given":"Wenrui","family":"Duan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirley","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Dotts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Fink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjun","family":"Kalvala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany","family":"Aguila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi-En","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel A.","family":"Villalona-Calero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,24]]},"reference":[{"key":"83884_CR1","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-cancerbio-030617-050422","volume":"3","author":"J Niraj","year":"2019","unstructured":"Niraj, J., F\u00e4rkkil\u00e4, A. & D\u2019Andrea, A. D. The Fanconi anemia pathway in cancer. Annu. Rev. Cancer Biol. 3, 457\u2013478 (2019).","journal-title":"Annu. Rev. Cancer Biol."},{"key":"83884_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13578-020-00401-7","volume":"10","author":"W Liu","year":"2020","unstructured":"Liu, W. et al. Fanconi anemia pathway as a prospective target for cancer intervention. Cell Biosci. 10, 39 (2020).","journal-title":"Cell Biosci."},{"key":"83884_CR3","doi-asserted-by":"publisher","first-page":"5093","DOI":"10.1093\/hmg\/ddv227","volume":"24","author":"EL Virts","year":"2015","unstructured":"Virts, E. L. et al. AluY-mediated germline deletion, duplication and somatic stem cell reversion in UBE2T defines a new subtype of Fanconi anemia. Hum. Mol. Genet. 24, 5093\u20135108 (2015).","journal-title":"Hum. Mol. Genet."},{"key":"83884_CR4","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1136\/jmedgenet-2016-103847","volume":"53","author":"JY Park","year":"2016","unstructured":"Park, J. Y. Complementation of hypersensitivity to DNA interstrand crosslinking agents demonstrates that XRCC2 is a Fanconi anaemia gene. J. Med. Genet. 53, 672\u2013680 (2016).","journal-title":"J. Med. Genet."},{"key":"83884_CR5","doi-asserted-by":"publisher","first-page":"3580","DOI":"10.1172\/JCI88010","volume":"126","author":"D Bluteau","year":"2016","unstructured":"Bluteau, D. et al. Biallelic inactivation of REV7 is associated with Fanconi anemia. J. Clin. Invest. 126, 3580\u20133584 (2016).","journal-title":"J. Clin. Invest."},{"key":"83884_CR6","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1172\/JCI92069","volume":"127","author":"K Knies","year":"2017","unstructured":"Knies, K. et al. Biallelic mutations in the ubiquitin ligase RFWD3 cause Fanconi anemia. J. Clin. Invest. 127, 3013\u20133027 (2017).","journal-title":"J. Clin. Invest."},{"key":"83884_CR7","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/nrg2159","volume":"8","author":"W Wang","year":"2007","unstructured":"Wang, W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat. Rev. Genet. 8, 735\u2013748 (2007).","journal-title":"Nat. Rev. Genet."},{"key":"83884_CR8","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.trsl.2012.09.003","volume":"161","author":"W Duan","year":"2013","unstructured":"Duan, W. et al. Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents. Transl. Res. 161, 156\u2013164 (2013).","journal-title":"Transl. Res."},{"key":"83884_CR9","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3389\/fonc.2014.00368","volume":"4","author":"W Duan","year":"2014","unstructured":"Duan, W. et al. Fanconi anemia repair pathway dysfunction, a potential therapeutic target in lung cancer. Front. Oncol. 4, 368 (2014).","journal-title":"Front. Oncol."},{"key":"83884_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12964-017-0195-9","volume":"15","author":"S Bhattacharjee","year":"2017","unstructured":"Bhattacharjee, S. & Nandi, S. DNA damage response and cancer therapeutics through the lens of the Fanconi Anemia DNA repair pathway. Cell Commun. Signal. 15, 41 (2017).","journal-title":"Cell Commun. Signal."},{"key":"83884_CR11","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913\u2013917 (2005).","journal-title":"Nature"},{"key":"83884_CR12","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917\u2013921 (2005).","journal-title":"Nature"},{"key":"83884_CR13","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1093\/jnci\/djv437","volume":"108","author":"MA Villalona-Calero","year":"2016","unstructured":"Villalona-Calero, M. A. et al. Veliparib alone or in combination with mitomycin C in patients with solid tumors with functional deficiency in homologous recombination repair. J. Natl. Cancer Inst. 108, 437 (2016).","journal-title":"J. Natl. Cancer Inst."},{"key":"83884_CR14","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nrm.2016.48","volume":"17","author":"R Ceccaldi","year":"2016","unstructured":"Ceccaldi, R., Sarangi, P. & D\u2019Andrea, A. D. The Fanconi anaemia pathway: new players and new functions. Nat. Rev. Mol. Cell Biol. 17, 337\u2013349 (2016).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"83884_CR15","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1016\/j.celrep.2017.05.081","volume":"19","author":"RS Cheung","year":"2017","unstructured":"Cheung, R. S. et al. Ubiquitination-linked phosphorylation of the FANCI S\/TQ cluster contributes to activation of the Fanconi anemia I\/D2 complex. Cell Rep. 19, 2432\u20132440 (2017).","journal-title":"Cell Rep."},{"key":"83884_CR16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.cell.2007.03.009","volume":"129","author":"A Smogorzewska","year":"2007","unstructured":"Smogorzewska, A. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell 129, 289\u2013301 (2007).","journal-title":"Cell"},{"key":"83884_CR17","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.molcel.2006.06.024","volume":"23","author":"YJ Machida","year":"2006","unstructured":"Machida, Y. J. et al. UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. Mol. Cell. 23, 589\u2013596 (2006).","journal-title":"Mol. Cell."},{"key":"83884_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.4161\/cc.3.2.656","volume":"3","author":"AR Meetei","year":"2004","unstructured":"Meetei, A. R., Yan, Z. & Wang, W. FANCL replaces BRCA1 as the likely ubiquitin ligase responsible for FANCD2 monoubiquitination. Cell Cycle 3, 179\u2013181 (2004).","journal-title":"Cell Cycle"},{"key":"83884_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/ng1241","volume":"35","author":"AR Meetei","year":"2003","unstructured":"Meetei, A. R. et al. A novel ubiquitin ligase is deficient in Fanconi anemia. Nat. Genet. 35, 165\u2013170 (2003).","journal-title":"Nat. Genet."},{"key":"83884_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.blre.2016.10.002","volume":"31","author":"NE Mamrak","year":"2017","unstructured":"Mamrak, N. E., Shimamura, A. & Howlett, N. G. Recent discoveries in the molecular pathogenesis of the inherited bone marrow failure syndrome Fanconi anemia. Blood Rev. 31, 93\u201399 (2017).","journal-title":"Blood Rev."},{"key":"83884_CR21","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.molcel.2017.04.021","volume":"66","author":"L Feeney","year":"2017","unstructured":"Feeney, L. et al. RPA-mediated recruitment of the E3 Ligase RFWD3 is vital for interstrand crosslink repair and human health. Mol. Cell. 66, 610\u2013621 (2017).","journal-title":"Mol. Cell."},{"key":"83884_CR22","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.molcel.2017.04.022","volume":"66","author":"S Inano","year":"2017","unstructured":"Inano, S. et al. RFWD3-mediated ubiquitination promotes timely removal of both RPA and RAD51 from DNA damage sites to facilitate homologous recombination. Mol. Cell. 66, 622\u2013634 (2017).","journal-title":"Mol. Cell."},{"key":"83884_CR23","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.molcel.2005.01.008","volume":"17","author":"SM Nijman","year":"2005","unstructured":"Nijman, S. M. et al. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell. 17, 331\u2013339 (2005).","journal-title":"Mol Cell."},{"key":"83884_CR24","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1262\/jrd.2015-167","volume":"62","author":"P Tulay","year":"2016","unstructured":"Tulay, P. & Sengupta, S. B. MicroRNA expression and its association with DNA repair in preimplantation embryos. J. Reprod. Dev. 62, 225\u2013234 (2016).","journal-title":"J. Reprod. Dev."},{"key":"83884_CR25","doi-asserted-by":"publisher","first-page":"8866","DOI":"10.1073\/pnas.0800650105","volume":"105","author":"YW Kong","year":"2008","unstructured":"Kong, Y. W. et al. The mechanism of micro-RNA-mediated translation repression is determined by the promoter of the target gene. Proc. Natl. Acad. Sci. USA 105, 8866\u20138871 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"83884_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1245\/s10434-013-3240-y","volume":"21","author":"AL Collins","year":"2014","unstructured":"Collins, A. L. et al. A differential microRNA profile distinguishes cholangiocarcinoma from pancreatic adenocarcinoma. Ann. Surg. Oncol. 21, 133\u2013138 (2014).","journal-title":"Ann. Surg. Oncol."},{"key":"83884_CR27","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00428-014-1640-4","volume":"465","author":"MK Kim","year":"2014","unstructured":"Kim, M. K. Expression of microRNA miR-126 and miR-200c is associated with prognosis in patients with non-small cell lung cancer. Virchows Arch. 465, 463\u2013471 (2014).","journal-title":"Virchows Arch."},{"key":"83884_CR28","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.molonc.2012.09.006","volume":"6","author":"MD Jansson","year":"2012","unstructured":"Jansson, M. D. & Lund, A. H. MicroRNA and cancer. Mol. Oncol. 6, 590\u2013610 (2012).","journal-title":"Mol. Oncol."},{"key":"83884_CR29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fcell.2017.00086","volume":"5","author":"S Detassis","year":"2017","unstructured":"Detassis, S., Grasso, M., Del Vescovo, V. & Denti, M. A. microRNAs make the call in cancer personalized medicine. Front Cell Dev Biol. 5, 86 (2017).","journal-title":"Front Cell Dev Biol."},{"key":"83884_CR30","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/nrc1997","volume":"6","author":"GA Calin","year":"2016","unstructured":"Calin, G. A. & Croce, C. M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 6, 857\u2013866 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"83884_CR31","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nrg1379","volume":"5","author":"L He","year":"2004","unstructured":"He, L. & Hannon, G. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 5, 522\u2013531 (2004).","journal-title":"Nat. Rev. Genet."},{"key":"83884_CR32","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3892\/ijo.2013.1963","volume":"43","author":"M Pacurari","year":"2013","unstructured":"Pacurari, M. et al. The microRNA-200 family targets multiple non-small cell lung cancer prognostic markers in H1299 cells and BEAS-2B cells. Int. J. Oncol. 43, 548\u2013560 (2013).","journal-title":"Int. J. Oncol."},{"key":"83884_CR33","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.bbrc.2015.08.127","volume":"466","author":"B Suresh","year":"2015","unstructured":"Suresh, B. et al. Regulation of Fanconi anemia protein FANCD2 monoubiquitination by miR-302. Biochem. Biophys. Res. Commun. 466, 180\u2013185 (2015).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"83884_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.acr.2017.06.005","volume":"135","author":"A Drusco","year":"2017","unstructured":"Drusco, A. & Croce, C. M. MicroRNAs and cancer: a long story for short RNAs. Adv Cancer Res. 135, 1\u201324 (2017).","journal-title":"Adv Cancer Res."},{"issue":"16","key":"83884_CR35","first-page":"30564","volume":"S0378\u20131119","author":"W Shan","year":"2016","unstructured":"Shan, W., Zhang, X., Li, M., Deng, F. & Zhang, J. Over expression of miR-200c suppresses invasion and restores methotrexate sensitivity in lung cancer A549 cells. Gene S0378\u20131119(16), 30564\u201330569 (2016).","journal-title":"Gene"},{"key":"83884_CR36","doi-asserted-by":"publisher","first-page":"E95","DOI":"10.3390\/genes8030095","volume":"8","author":"D Ayers","year":"2017","unstructured":"Ayers, D. & Vandesompele, J. Influence of microRNAs and Long Non-Coding RNAs in Cancer Chemoresistance. Genes (Basel). 8, E95 (2017).","journal-title":"Genes (Basel)."},{"key":"83884_CR37","doi-asserted-by":"publisher","first-page":"46243","DOI":"10.1074\/jbc.M207937200","volume":"277","author":"SL Donahue","year":"2002","unstructured":"Donahue, S. L. & Campbell, C. A DNA double strand break repair defect in Fanconi anemia fibroblasts. J. Biol. Chem. 277, 46243\u201346247 (2002).","journal-title":"J. Biol. Chem."},{"key":"83884_CR38","doi-asserted-by":"crossref","unstructured":"Kulkarni, M. M. Digital multiplexed gene expression analysis using the NanoString nCounter system. Curr Protoc Mol Biol. Chapter 25:Unit25B (2011).","DOI":"10.1002\/0471142727.mb25b10s94"},{"key":"83884_CR39","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/ijc.25049","volume":"127","author":"W Duan","year":"2010","unstructured":"Duan, W. et al. MicroRNA-34a is an important component of PRIMA-1-induced apoptotic network in human lung cancer cells. Int. J. Cancer. 127, 313\u2013320 (2010).","journal-title":"Int. J. Cancer."},{"key":"83884_CR40","doi-asserted-by":"publisher","first-page":"65457","DOI":"10.18632\/oncotarget.18924","volume":"8","author":"T Koo","year":"2017","unstructured":"Koo, T. et al. MicroRNA-200c increases radiosensitivity of human cancer cells with activated EGFR-associated signaling. Oncotarget. 8, 65457\u201365468 (2017).","journal-title":"Oncotarget."},{"key":"83884_CR41","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1101\/gad.1640608","volume":"22","author":"S-M Park","year":"2008","unstructured":"Park, S.-M., Gaur, A. B., Lengyel, E. & Peter, M. E. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 22, 894\u2013907 (2008).","journal-title":"Genes Dev."},{"key":"83884_CR42","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1158\/1078-0432.CCR-08-2245","volume":"15","author":"L Adam","year":"2009","unstructured":"Adam, L. et al. miR-200 expression regulates epithelialto-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin. Cancer Res. 15, 5060\u20135072 (2009).","journal-title":"Clin. Cancer Res."},{"key":"83884_CR43","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/1476-4598-13-166","volume":"13","author":"J Li","year":"2014","unstructured":"Li, J. et al. miRNA-200c inhibits invasion and metastasis of human non-small cell lung cancer by directly targeting ubiquitin specific peptidase 25. Mol. Cancer. 13, 166 (2014).","journal-title":"Mol. Cancer."},{"key":"83884_CR44","doi-asserted-by":"publisher","first-page":"e101899","DOI":"10.1371\/journal.pone.0101899","volume":"9","author":"R Tejero","year":"2014","unstructured":"Tejero, R. et al. miR-141 and miR-200c as markers of overall survival in early stage non-small cell lung cancer adenocarcinoma. PLoS ONE 9, e101899 (2014).","journal-title":"PLoS ONE"},{"key":"83884_CR45","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.3892\/mmr.2016.4901","volume":"13","author":"A Jiao","year":"2016","unstructured":"Jiao, A. et al. MicroRNA-200c inhibits the metastasis of non-small cell lung cancer cells by targeting ZEB2, an epithelial-mesenchymal transition regulator. Mol. Med. Rep. 13, 3349\u20133355 (2016).","journal-title":"Mol. Med. Rep."},{"key":"83884_CR46","doi-asserted-by":"publisher","first-page":"e0180844","DOI":"10.1371\/journal.pone.0180844","volume":"12","author":"PL Liu","year":"2017","unstructured":"Liu, P. L. et al. MicroRNA-200c inhibits epithelial-mesenchymal transition, invasion, and migration of lung cancer by targeting HMGB1. PLoS ONE 12, e0180844 (2017).","journal-title":"PLoS ONE"},{"key":"83884_CR47","doi-asserted-by":"publisher","first-page":"185","DOI":"10.18632\/oncotarget.1427","volume":"5","author":"F Kopp","year":"2014","unstructured":"Kopp, F., Wagner, E. & Roidl, A. The proto-oncogene KRAS is targeted by miR-200c. Oncotarget. 5, 185\u2013195 (2014).","journal-title":"Oncotarget."},{"key":"83884_CR48","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s00109-016-1420-5","volume":"94","author":"M Mutlu","year":"2016","unstructured":"Mutlu, M. et al. miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance. J. Mol. Med. 94, 629\u2013644 (2016).","journal-title":"J. Mol. Med."},{"key":"83884_CR49","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s12032-014-0428-3","volume":"32","author":"X Zhou","year":"2015","unstructured":"Zhou, X. et al. The downregulation of miR-200c\/141 promotes ZEB1\/2 expression and gastric cancer progression. Med. Oncol. 32, 428 (2015).","journal-title":"Med. Oncol."},{"issue":"6","key":"83884_CR50","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.31557\/APJCP.2019.20.6.1633","volume":"20","author":"B Nourmohammadi","year":"2019","unstructured":"Nourmohammadi, B. et al. Expression of miR-9 and miR-200c, ZEB1, ZEB2 and E-cadherin in non-small cell lung cancers in Iran. Asian Pac. J. Cancer Prev. 20(6), 1633\u20131639 (2019).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"83884_CR51","first-page":"91","volume":"39","author":"A Kurata","year":"2018","unstructured":"Kurata, A. et al. Expression level of microRNA-200c is associated with cell morphology in vitro and histological differentiation through regulation of ZEB1\/2 and E-cadherin in gastric carcinoma. Oncol. Rep. 39, 91\u2013100 (2018).","journal-title":"Oncol. Rep."},{"key":"83884_CR52","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nrclinonc.2014.5","volume":"11","author":"H Schwarzenbach","year":"2014","unstructured":"Schwarzenbach, H., Nishida, N., Calin, G. A. & Pantel, K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat. Rev. Clin. Oncol. 11, 145\u2013156 (2014).","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83884-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83884-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83884-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T21:31:39Z","timestamp":1697923899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83884-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,24]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["83884"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-83884-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,24]]},"assertion":[{"value":"28 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4420"}}